Safety Evaluation of Bioactive Glass Based Bone Cement Combined With Ultrasound in Implantation for Metastatic Bone Tumors

The NIH ClinicalTrials.gov registry has recorded a new Phase safety trial (NCT07540468) evaluating the use of bioactive glass-containing bone cement combined with intraoperative ultrasound for patients with metastatic bone tumors. The study will assess whether this combined treatment approach can safely stabilize bone and reduce pain without causing unexpected adverse events. All participants will receive standard care plus the study intervention.

Affected parties include hospitals, orthopedic and surgical oncology departments conducting bone tumor procedures, and medical device manufacturers producing bone cements or surgical ultrasound equipment. While this is an informational trial registration rather than a regulatory action, sponsors and manufacturers of similar bone cement products may wish to monitor trial outcomes for competitive intelligence and potential FDA regulatory pathway implications.